|
Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials. |
|
|
Stock and Other Ownership Interests - Gilead Sciences; illumina |
Consulting or Advisory Role - Ventana Medical Systems |
Travel, Accommodations, Expenses - ventana medical systems |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Baxter; Biothera; Forty Seven; Immunocare Therapies; Immunovative Therapies; kanghong Pharma; Lilly; Merck; Momenta Pharmaceuticals; Novo Nordisk; Pfizer; Sirtex Medical; Taiho Pharmaceutical; Targovax |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Immunomedics (Inst); Merck (Inst); Sanofi (Inst) |
Travel, Accommodations, Expenses - Amgen; Baxter; Merck KGaA; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Acerta Pharma; ARIAD; Astellas Pharma; AstraZeneca/MedImmune; Biothera; Celldex; Exelixis; Genentech; Incyte; Kyowa Hakko Kirin; Medivation; Merck; Merrimack; Nektar; Novartis; Pharmacyclics; Pique; Spiration; Xbiotech |
Research Funding - Celgene (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Celgene |
|
|
No Relationships to Disclose |